Compare GPCR & HTGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GPCR | HTGC |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | N/A | 50 |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2023 | N/A |
| Metric | GPCR | HTGC |
|---|---|---|
| Price | $44.81 | $15.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $103.17 | $18.86 |
| AVG Volume (30 Days) | 701.2K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 12.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.18 |
| Revenue Next Year | N/A | $5.24 |
| P/E Ratio | ★ N/A | $8.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.80 | $13.70 |
| 52 Week High | $94.90 | $19.67 |
| Indicator | GPCR | HTGC |
|---|---|---|
| Relative Strength Index (RSI) | 61.56 | 49.23 |
| Support Level | $42.72 | $15.22 |
| Resistance Level | $57.23 | $15.96 |
| Average True Range (ATR) | 2.20 | 0.28 |
| MACD | 0.91 | 0.01 |
| Stochastic Oscillator | 74.71 | 60.87 |
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.